Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 43 clinical trials
Acute Effects of Chemotherapy Administration on Skeletal Muscle of Breast Cancer Patients: the PROTECT-06 Study (PROTECT-06)

Chemotherapy treatments such as epirubicin-cyclophosphamid or paclitaxel lead to severe off-target side effects such as skeletal muscle deconditioning. To date, three different studies

paclitaxel
cyclophosphamide
epirubicin
  • 0 views
  • 23 Apr, 2022
  • 1 location
Atherosclerosis in Chemotherapy-related Cardiotoxicity (ANTEC)

group of 80 patients diagnosed with cancer before starting high-dose anthracycline chemotherapy (doxorubicin ≥ 240 mg / m2 or epirubicin ≥ 540 mg / m2 body weight), without a history of heart failure

heart failure
myocardial infarction
stroke
hmg-coa reductase inhibitor
infarction
  • 0 views
  • 10 Mar, 2022
  • 1 location
Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer

Neoadjuvant (preoperative) chemotherapy is an interesting research tool which allows investigators to test new drugs and/or new schedules with a validated surrogate endpoint, pCR. It also represents an ideal model to evaluate the relationships between treatments and tumor biomarkers. Recent publications have shown that new molecular classifications of breast cancer …

taxane
invasive breast cancer
BRCA1
docetaxel
triple negative breast cancer
  • 0 views
  • 04 Sep, 2021
  • 1 location